Source-grounded facts extracted from Karyopharm Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Ran Frenkel departed as Executive Vice President, Chief Development Officer at Karyopharm Therapeutics Inc..
“On July 26, 2022, Karyopharm Therapeutics Inc. (the “Company”) and Ran Frenkel agreed that Mr. Frenkel will cease to serve as the Company’s Executive Vice President, Chief Development Officer effective August 15, 2022.”
Sharon Shacham resigned as Chief Scientific Officer at Karyopharm Therapeutics Inc..
“provides for Dr. Shacham’s separation from employment as Chief Scientific Officer on the Separation Date”
Michael G. Kauffman resigned as Senior Clinical Advisor at Karyopharm Therapeutics Inc..
“provides for Dr. Kauffman’s separation from employment as Senior Clinical Advisor on May 31, 2022”
Michael G. Kauffman resigned as Director at Karyopharm Therapeutics Inc..
“On March 22, 2022, Michael G. Kauffman, M.D., Ph.D. notified Karyopharm Therapeutics Inc. (the “Company”) of his resignation from the Board of Directors, effective immediately.”
Peter Honig was elected as Director at Karyopharm Therapeutics Inc..
“On December 3, 2021, the Board, upon the recommendation of the Nominating, Corporate Governance & Compliance Committee of the Board, elected Peter K Honig, M.D., MPH, as an independent director of the Company to fill a vacancy on the Board.”
Mikael Dolsten resigned as Director at Karyopharm Therapeutics Inc..
“On December 2, 2021, Mikael Dolsten, MD, PhD, notified Karyopharm Therapeutics Inc. (the “Company”) of his resignation from the Board of Directors (the “Board”), effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.